A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma (Q34764827)

4 August 2017

title

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma (English)

1 reference

4 August 2017

1 reference

Mark J McKeage

3

0 references

Philip Savage

object named as

Philip Savage

4

0 references

James Spicer

1 reference

ORCID Public Data File 2021

author name string

Sarah M Rudman

1

1 reference

4 August 2017

Michael B Jameson

2

1 reference

4 August 2017

Duncan I Jodrell

5

1 reference

4 August 2017

Mark Harries

6

1 reference

4 August 2017

Gary Acton

7

1 reference

4 August 2017

Fredrik Erlandsson

8

1 reference

4 August 2017

James F Spicer

9

1 reference

4 August 2017

language of work or name

English

0 references

publication date

29 March 2011

1 reference

4 August 2017

published in

Clinical Cancer Research

1 reference

4 August 2017

volume

17

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

1998-2005

1 reference

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071333

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21447719

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21447719

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21447719

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-10-2490

1 reference

4 August 2017

1 reference

4 August 2017

1 reference